

Product datasheet for TR308636

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

TRIP230 (TRIP11) Human shRNA Plasmid Kit (Locus ID 9321)

Product data:

Product Type: shRNA Plasmids

Locus ID: 9321

Synonyms: ACG1A; CEV14; GMAP-210; GMAP210; ODCD; ODCD1; TRIP-11; TRIP230

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

Components: TRIP11 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

9321). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: <u>NM_001321851</u>, <u>NM_004239</u>, <u>NM_004239.1</u>, <u>NM_004239.2</u>, <u>NM_004239.3</u>, <u>NM_004239.4</u>,

BC002656, BC069008, BC146845, BM770594

UniProt ID: Q15643

Summary: This gene was identified based on the interaction of its protein product with thyroid hormone

receptor beta. This protein is associated with the Golgi apparatus. The N-terminal region of the protein binds Golgi membranes and the C-terminal region binds the minus ends of microtubules; thus, the protein is thought to play a role in assembly and maintenance of the Golgi ribbon structure around the centrosome. Mutations in this gene cause achondrogenesis

type IA. [provided by RefSeq, Mar 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact $\underline{\mathsf{techsupport}} \underline{\mathsf{oorigene.com}}.$

If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

> For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).